Artificial Intelligence in COVID-19 Management: A Systematic Review

With the development of modern technologies in the field of healthcare, the use of Artificial Intelligence (AI) in disease management is increasing. AI methods may assist healthcare providers in the COVID-19 era. The current study aimed to observe the efficacy and importance of AI for managing the COVID-19 pandemic. An organized search was conducted, utilizing PubMed, Web of Science, Scopus, Embase, and Cochrane up to September 2022. Studies were considered qualified for inclusion if they met the inclusion criterion. We conducted review according to the Preferred Reporting Items for Systematic reviews and Meta Analyses (PRISMA) guidelines. There were 52 documents that met the eligibility criteria to be included in the review. The most common item using AI during the COVID-19 era was predictive models to foretell pneumonia and mortality risks in people with COVID-19 based on medical and experimental parameters. COVID-19 mortality was related to being male and elderly based on the Artificial Neural Network (ANN) and Convolutional Neural Network (CNN) logistic regression analysis of demographics, clinical data, and laboratory tests of hospitalized COVID-19 patients. AI can predict, diagnose and model COVID-19 by using techniques such as support vector machines, decision trees, and neural networks. It is suggested that future research should deal with the design and development of AI-based tools for the management of chronic diseases such as COVID-19. © 2023 Samaneh Mohammadi, SeyedAhmad SeyedAlinaghi, Mohammad Heydari, Zahra Pashaei, Pegah Mirzapour, Amirali Karimi, Amir Masoud Afsahi, Peyman Mirghaderi, Parsa Mohammadi, Ghazal Arjmand, Yasna Soleimani, Ayein Azarnoush, Hengameh Mojdeganlou, Mohsen Dashti, Hadiseh Azadi Cheshmekabodi, Sanaz Varshochi, Mohammad Mehrtak, Ahmadreza Shamsabadi, Esmaeil Mehraeen, and Daniel Hackett. This open-access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license.

Investigation of Effective Drugs in the Treatment of Patients with COVID-19

Background: Due to the lack of definitive treatments for corona disease and the use of various medications in protocols around the world, it is necessary to conduct more epidemiological studies exploring the effect of different available therapeutic regimes;therefore, the present study aimed to explore the current effective drugs for the treatment of hospitalized COVID-19 patients. Methods: The present study is a descriptive-analytical study that was conducted between August and September of 2021 at Khalkhal University of Medical Sciences. A convenient sampling method was employed to retrieve the data from the available hospital records, including 252 documents from COVID-19 hospitalized patients. A researcher-made checklist was used to record the data. Data were analyzed using SPSS 26 software. Results: The findings showed that Hypertension and Hypotension (n=47,18.7%) are the most common underlying diseases in the study sample. The most therapeutic regimen was the combination of Remdesivir and Dexametason (n=137,54.4%) in hospitalized COVID-19 patients. There are a variety of organ involvements and presentations to the COVID-19;however, most patients experience a mild-to-moderate, self-limited disease;even though, the disease could progress to more fatal cases and lead to death. Conclusion: The main pathology exists in the lungs which are caused by an inappropriate immune response that leads to a severe inflammatory response. Therefore, antiviral and anti-inflammatory drugs are currently the first-line therapy for hospitalized patients. Copyright 2023, Journal of Iranian Medical Council.